A Phase II Study of Abemaciclib for Patients with Recurrent Glioblastoma


Full Title

A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma


The purpose of this study is to assess the safety and effectiveness of the drug abemaciclib in patients with glioblastoma that has come back despite prior treatment that included radiation therapy and/or temozolomide. Abemaciclib is designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide. It is approved for treating metastatic breast cancer; its use in this study is investigational.

Patients who are having surgery will take abemaciclib before and after surgery. Those who are not having surgery will take abemaciclib alone. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have glioblastoma that has come back despite one prior regimen of treatment with radiation therapy and/or temozolomide (first relapse).
  • At least 12 weeks must pass since the completion of radiation therapy and 23 days since temozolomide (4 weeks since any other anticancer drugs) and entry into the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Mariza Daras at 212-610-0239.





Disease Status

Relapsed or Refractory